secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001104659-24-059136
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise Q1 net loss $28.5M; sevasemten shows positive Becker data
------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $532.8M as of March 31, 2024.
- Net loss $28.5M ($0.33 per share) vs $30.1M ($0.47) prior quarter.
- Sevasemten ARCH 2-year: NSAA stabilized, CK and TNNI2 decreased; DUNE showed 45% CK reduction vs placebo.
- GRAND CANYON pivotal cohort recruiting ~120 patients with Becker; data expected Q4 2024.
- EDG-7500 Phase 2 CIRRUS-HCM trial initiated; first patient dosed April 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465924059136/0001104659-24-059136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465924059136/tm2413446d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-059136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer